SUMATRIPTAN INJECTION, USP SOLUTION

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

SUMATRIPTAN (SUMATRIPTAN SUCCINATE)

Sẵn có từ:

STERIMAX INC

Mã ATC:

N02CC01

INN (Tên quốc tế):

SUMATRIPTAN

Liều dùng:

6MG

Dạng dược phẩm:

SOLUTION

Thành phần:

SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 6MG

Tuyến hành chính:

SUBCUTANEOUS

Các đơn vị trong gói:

0.5ML

Loại thuốc theo toa:

Prescription

Khu trị liệu:

SELECTIVE SEROTONIN AGONISTS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0123238006; AHFS:

Tình trạng ủy quyền:

APPROVED

Ngày ủy quyền:

2023-01-18

Đặc tính sản phẩm

1
PRODUCT MONOGRAPH
PR
SUMATRIPTAN INJECTION, USP
6 MG/0.5 ML
SUMATRIPTAN (AS SUMATRIPTAN SUCCINATE)
SUBCUTANEOUS INJECTION AND AUTOINJECTOR
5-HT
1
Receptor Agonist
Migraine Therapy
SteriMax Inc. Date of Revision:
2770 Portland Drive JAN 13, 2023
Oakville, Ontario
L6H 6R4
Control number: 270786
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY
PRODUCT
INFORMATION
................................................................................
3
INDICATIONS
AND
CLINICAL
USE
......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS
AND
PRECAUTIONS
..........................................................................................
5
ADVERSE
REACTIONS
.........................................................................................................
10
DRUG
INTERACTIONS
..........................................................................................................
13
DOSAGE
AND
ADMINISTRATION
......................................................................................
14
OVERDOSAGE
........................................................................................................................
15
ACTION
AND
CLINICAL
PHARMACOLOGY
.....................................................................
16
STORAGE
AND
STABILITY
..................................................................................................
17
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ...................................................... 17
PART II: SCIENTIFIC INFORMATION
...............................................................................
18
PHARMACEUTICAL
INFORMATION..................................................................................
18
CLINICAL
TRIALS
................................................................................